Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Bob Kronemyer
Start-Up Spotlight: Arkis BioSciences, Endexo-Boosted Ventricular Drainage Catheter Reduces Obstructions
Arkis BioSciences Inc.'s newly launched CerebroFlo EVD catheter for treating intracranial hypertension offers an added benefit of being impregnated with Endexo, an antiocclusive agent that in laboratory studies has shown to dramatically reduce the incidence of thrombus formation, which can potentially reduce catheter obstructions.
The global market for ophthalmic drugs is expected to hit $30.5bn by 2020, fueled in part by the rise in age-related eye conditions like glaucoma, dry eye and macular degeneration. However, there is still an unmet demand for technologies that can deliver these drugs effectively and over a sustained period. This article discusses what the challenges are to developing effective ocular drug delivery systems and highlights several innovative technologies in the pipeline, designed to overcome the limitations of current ophthalmic therapies and potentially accelerate growth of the market.
Restoring the eyes' ability to accommodate and seamlessly focus on near and far objects continues to be the holy grail in ophthalmology. Accommodating intraocular lenses offer one approach to tackle presbyopia and allow patients the possibility of eschewing reading glasses. LensGen is one company going down that road and it successfully raised $21m in series A financing – with major optical lens maker Hoya among its backers – in April to advance its fluid-based accommodating IOL, Juvene.
Start-Up Spotlight: Atlantic Therapeutics, Stimulating The Stress Incontinence Market With Vaginal Mesh Alternative
While controversy over vaginal mesh implants and the serious complications resulting from these devices eroding inside the patient continue unabated across the globe, one Irish company is looking to capitalize on this opportune time by offering a noninvasive solution to stress urinary incontinence. Atlantic Therapeutics has recently won the backing of European healthcare VCs, raising €15m in a Series A round.
Genetesis raised $1.2m in seed funding last year to advance development of its noninvasive, radiation-free tool to map the heart’s electrical activity and enable detection of any cardiac abnormalities. The company will initially market the technology for use in chest pain triage in the emergency room.
Originating from aerospace technology, Bio2 Technologies’ Vitrium biomaterial platform is designed for multiple applications across musculoskeletal surgery. The firm has already begun commercialization in the US and expects to get a CE mark later this year.